Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest

Key Points

Key points are not available for this paper at this time.

Abstract

The FOLFOXIRI regimen improves RR, PFS, and OS compared with FOLFIRI, with an increased, but manageable, toxicity in patients with metastatic colorectal cancer with favorable prognostic characteristics. Further studies of FOLFOXIRI in combination with targeted agents and in the neoadjuvant setting are warranted.

Bookmark

View Full Paper

Cite This Study

Falcone et al. (Mon,) studied this question.

synapsesocial.com/papers/69dca88ea5c75be4cfe5352e https://doi.org/https://doi.org/10.1200/jco.2006.09.0928

Bookmark

View Full Paper